Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers

Nicholas J. Ashton, Marc Suárez-Calvet, Amanda Heslegrave, Abdul Hye, Cristina Razquin, Pau Pastor, Raquel Sanchez-Valle, José L. Molinuevo, Pieter Jelle Visser, Kaj Blennow, Angela K. Hodges, Henrik Zetterberg

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background: Results from recent clinical studies suggest that cerebrospinal fluid (CSF) biomarkers that are indicative of Alzheimer's disease (AD) can be replicated in blood, e.g. amyloid-beta peptides (Aβ42 and Aβ40) and neurofilament light chain (NFL). Such data proposes that blood is a rich source of potential biomarkers reflecting central nervous system pathophysiology and should be fully explored for biomarkers that show promise in CSF. Recently, soluble fragments of the triggering receptor expressed on myeloid cells 2 (sTREM2) protein in CSF have been reported to be increased in prodromal AD and also in individuals with TREM2 rare genetic variants that increase the likelihood of developing dementia. Methods: In this study, we measured the levels of plasma sTREM2 and plasma NFL using the MesoScale Discovery and single molecule array platforms, respectively, in 48 confirmed TREM2 rare variant carriers and 49 non-carriers. Results: Our results indicate that there are no changes in plasma sTREM2 and NFL concentrations between TREM2 rare variant carriers and non-carriers. Furthermore, plasma sTREM2 is not different between healthy controls, mild cognitive impairment (MCI) or AD. Conclusion: Concentrations of plasma sTREM2 do not mimic the recent changes found in CSF sTREM2.
Original languageEnglish
Article number94
JournalAlzheimer's Research and Therapy
Volume11
Issue number1
DOIs
Publication statusPublished - 2019

Cite this

Ashton, N. J., Suárez-Calvet, M., Heslegrave, A., Hye, A., Razquin, C., Pastor, P., ... Zetterberg, H. (2019). Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers. Alzheimer's Research and Therapy, 11(1), [94]. https://doi.org/10.1186/s13195-019-0545-5